Dashboard
1
Poor Management Efficiency with a low ROCE of 2.16%
- The company has been able to generate a Return on Capital Employed (avg) of 2.16% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Positive results in Mar 25
4
With ROE of 5.02%, it has a expensive valuation with a 0.69 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 345 Million (Micro Cap)
14.00
NA
0.00%
-0.63
5.02%
0.69
Revenue and Profits:
Net Sales:
55 Million
(Quarterly Results - Jun 2025)
Net Profit:
8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.16%
0%
0.16%
6 Months
20.33%
0%
20.33%
1 Year
33.78%
0%
33.78%
2 Years
3.97%
0%
3.97%
3 Years
19.53%
0%
19.53%
4 Years
-7.98%
0%
-7.98%
5 Years
0%
0%
0.0%
AVE Science & Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.36%
EBIT Growth (5y)
-5.73%
EBIT to Interest (avg)
7.47
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.40
Tax Ratio
2.56%
Dividend Payout Ratio
29.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.16%
ROE (avg)
4.79%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.69
EV to EBIT
2.47
EV to EBITDA
1.20
EV to Capital Employed
0.15
EV to Sales
0.13
PEG Ratio
2.24
Dividend Yield
NA
ROCE (Latest)
6.21%
ROE (Latest)
5.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
55.20
49.50
11.52%
Operating Profit (PBDIT) excl Other Income
9.30
7.20
29.17%
Interest
0.00
0.00
Exceptional Items
0.00
-0.00
Consolidate Net Profit
7.70
6.50
18.46%
Operating Profit Margin (Excl OI)
114.80%
89.90%
2.49%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 11.52% vs -6.07% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 18.46% vs -9.72% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
199.50
196.50
1.53%
Operating Profit (PBDIT) excl Other Income
20.60
17.30
19.08%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
22.80
21.50
6.05%
Operating Profit Margin (Excl OI)
43.70%
31.70%
1.20%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.53% vs 1.71% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 6.05% vs 19.44% in Dec 2023
About AVE Science & Technology Co., Ltd. 
AVE Science & Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






